<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04546906</url>
  </required_header>
  <id_info>
    <org_study_id>CD22 CAR-T for B-ALL</org_study_id>
    <nct_id>NCT04546906</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Senlang Biotechnology Inc., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Senlang Biotechnology Inc., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD22&#xD;
      CAR-T cell in the treatment of recurrent or refractory B-ALL&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CARs consist of an anti-CD22 single-chain variable fragment（scFv）, a portion of the human&#xD;
      CD137（4-1BB） molecule, and the intracellular component of the human CD3ζ molecule. Prior to&#xD;
      CAR-T cell infusion, the patients will be subjected to preconditioning treatment. After CAR-T&#xD;
      cell infusion, the patients will be evaluated for adverse reactions and efficacy.&#xD;
&#xD;
      The Main research objectives:&#xD;
&#xD;
      To evaluate the safety and efficacy of CD22CAR-T in patients with recurrent or refractory&#xD;
      B-ALL&#xD;
&#xD;
      The Secondary research objectives:&#xD;
&#xD;
      To investigate the cytokinetic characteristics of CD22CAR-T in patients with recurrent or&#xD;
      refractory B-ALL&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence and severity of adverse events</measure>
    <time_frame>First month post CAR-T cells infusion</time_frame>
    <description>To evaluate the possible adverse events occurred within first one month after CD22 CAR-T infusion, including the incidence and severity of symptoms such as cytokine release syndrome and neurotoxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Remission Rate</measure>
    <time_frame>3 months post CAR-T cells infusion</time_frame>
    <description>Remission Rate including complete remission(CR)、CR with incomplete blood count recovery(CRi)、No remission(NR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy:duration of response (DOR)</measure>
    <time_frame>24 months post CAR-T cells infusion</time_frame>
    <description>duration of response (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: progression-free survival (PFS)</measure>
    <time_frame>24 months post CAR-T cells infusion</time_frame>
    <description>progression-free survival (PFS) time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAR-T proliferation</measure>
    <time_frame>3 months post CAR-T cells infusion</time_frame>
    <description>the copy number of CD19 CAR- T cells in the genomes of PBMC by qPCR method and percentage of CD19 CAR- T cells measured by flow cytometry method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine release</measure>
    <time_frame>First month post CAR-T cells infusion</time_frame>
    <description>Cytokine( IL-6,IL-10,IFN-γ,TNF-α ) concentration (pg/mL) by flow cytometry method</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>B-ALL</condition>
  <arm_group>
    <arm_group_label>CD22 CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with CD22 CAR-T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD22 CAR-T</intervention_name>
    <description>Biological: CD22 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis</description>
    <arm_group_label>CD22 CAR-T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with relapsed and refractory acute B-lymphoblastic leukemia who have any of&#xD;
             the following:&#xD;
&#xD;
               1. B-ALL patients with relapse (including bone marrow morphological relapse 1 and&#xD;
                  minimal residual relapse 2) after remission by chemotherapy or autologous stem&#xD;
                  cell transplantation;&#xD;
&#xD;
               2. Primary B-ALL patients who can not be completely relieved by more than two times&#xD;
                  of repeated chemotherapy;&#xD;
&#xD;
               3. High risk primary B-ALL patients who have not been relieved but are not suitable&#xD;
                  for re intensive therapy after 1-2 times of chemotherapy;&#xD;
&#xD;
          2. Flow cytometry (FCM) showed CD 22 positive in bone marrow or peripheral blood;&#xD;
&#xD;
          3. There should be at least one assessable lesion in B-ALL patients with simple&#xD;
             extramedullary recurrence;&#xD;
&#xD;
          4. The activity state score of the Eastern Cooperative Oncology Group (ECOG) was less&#xD;
             than or equal to 2;&#xD;
&#xD;
          5. The estimated survival time is more than 3 months;&#xD;
&#xD;
          6. Need to sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious cardiac insufficiency；&#xD;
&#xD;
          2. Has a history of severe pulmonary function damaging;&#xD;
&#xD;
          3. Other malignant tumors;&#xD;
&#xD;
          4. Serious infection or persistent infection and can not be effectively controlled；&#xD;
&#xD;
          5. Merging severe autoimmune diseases or immunodeficiency disease;&#xD;
&#xD;
          6. Patients with active hepatitis (HBV DNA or HCV RNA positive);&#xD;
&#xD;
          7. Patients with HIV infection or syphilis infection;&#xD;
&#xD;
          8. Has a history of serious allergies on Biological products (including antibiotics);&#xD;
&#xD;
          9. Being pregnant and lactating or having pregnancy within 12 months;&#xD;
&#xD;
         10. Any situations that the researchers believe will increase the risks for the subject or&#xD;
             affect the results of the study（including a history of serious mental illness,&#xD;
             substance abuse and addiction）&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peihua Lu, PhD&amp;MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Yanda Ludaopei Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peihua Lu, PhD&amp;MD</last_name>
    <phone>008618611636172</phone>
    <email>peihua_lu@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianqiang Li, PhD&amp;MD</last_name>
    <phone>008615511369555</phone>
    <email>limmune@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hebei yanda Ludaopei Hospital</name>
      <address>
        <city>Heibei</city>
        <state>Sanhe</state>
        <zip>065200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peihua Lu, PhD&amp;MD</last_name>
      <phone>008618611636172</phone>
      <email>peihua_lu@126.com</email>
    </contact>
    <investigator>
      <last_name>Peihua Lu, PhD&amp;MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianqiang Li, PhD&amp;MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BeiJing Ludaopei Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Yizhuang</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peihua Lu, PhD&amp;MD</last_name>
      <phone>008618611636172</phone>
      <email>peihua_lu@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>September 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD22 CAR-T， B-ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

